Overview

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Status:
Not yet recruiting

Trial end date:
2023-08-30

Target enrollment:

Participant gender:

Summary

This is a multi-center, single-arm, open-label, Phase 2 clinical study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases.

Phase:

Phase 2

Details

Lead Sponsor:

Guangdong Association of Clinical Trials